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CardioprotectiveIn cardiac surgery, postoperative low cardiac output has been shown to correlate with increased rates of organ
failure and mortality. Catecholamines have been the standard therapy for many years, although they carry
substantial risk for adverse cardiac and systemic effects, and have been reported to be associated with increased
mortality. On the other hand, the calcium sensitiser and potassium channel opener levosimendan has been
shown to improve cardiac function with no imbalance in oxygen consumption, and to have protective effects
in other organs. Numerous clinical trials have indicated favourable cardiac and non-cardiac effects of preopera-
tive and perioperative administration of levosimendan. A panel of 27 experts from 18 countries has now
reviewed the literature on the use of levosimendan in on-pump and off-pump coronary artery bypass grafting
and in heart valve surgery. This panel discussed the published evidence in these various settings, and agreed to
vote on a set of questions related to the cardioprotective effects of levosimendan when administered preopera-
tively, with the purpose of reaching a consensus on which patients could beneﬁt from the preoperative use of
levosimendan and in which kind of procedures, and at which doses and timing should levosimendan be admin-
istered. Here, we present a systematic review of the literature to report on the completed and ongoing studies onlogy and Intensive Care Medicine, University Hospital of Graz, Auenbruggerplatz 29, 8036 Graz, Austria.
ller).
land Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
324 W. Toller et al. / International Journal of Cardiology 184 (2015) 323–336levosimendan, including the newly commenced LEVO-CTS phase III study (NCT02025621), and on the consensus
reached on the recommendations proposed for the use of preoperative levosimendan.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In patients undergoing cardiac surgery, low cardiac output syn-
drome (LCOS) is a disastrous event that can result in life-threatening
complications [1,2]. With LCOS, the mortality rate of these patients
can be as high as 16.9% (versus 0.9%without LCOS) [2]. Preoperative re-
duced left ventricular function has been recognised as themain risk fac-
tor for LCOS [3,4].
Cardiac surgery is also usually accompanied bymulti-faceted effects,
which include sympathetic activation, inﬂammation, and haemo-
dynamic changes, and is thus likely to promote organ dysfunction.
Of note, acute kidney injury is frequently observed after cardiac
surgery, and this is associated with increased long-term mortality
after cardiothoracic surgery [5]. Postoperative acute kidney injury
can be part of cardiorenal syndrome, which is a classic example of
organ dysfunction that can arise due to hypoperfusion, which trig-
gers a sympathoadrenergic response, hyperglycaemia and inﬂam-
mation [6].
Inotropic support is frequently initiated in the perioperative period
to improve post-bypass ventricular function. However, inotropes in-
clude the potential risk of increased myocardial oxygen consumption,
which can result in cardiac ischaemia, with subsequent damage to hi-
bernating but viable myocardium, and arrhythmias. This has prompted
anongoing debate on the potential harm associatedwith inotropic ther-
apy in cardiac surgery. Indeed, the use of perioperative and postopera-
tive inotropes has recently been found to be associated with increased
mortality and major postoperative morbidity [7].
Administration of the calcium sensitiser levosimendan, which has
been approved formanagement of acutely decompensated heart failure,
might offer a solution to this unmet need. The effects of levosimendan as
an inodilator are based on a triplemechanismof action [8] that provides
positive inotropy with a neutral effect on oxygen consumption [9], and
with preconditioning [10], cardioprotective [11], anti-stunning [12] and
anti-ischaemic effects [13]. In a recent meta-analysis of clinical trials,
Harrison and colleagues evaluated the effects of levosimendan in cardiac
surgery patients with andwithout preoperative systolic dysfunction [14].
Here, they showed that mortality and other adverse outcomes, such as
postoperative renal failure requiring dialysis, postoperative atrial ﬁbrilla-
tion, and myocardial injury, were reduced with levosimendan treatment.
These beneﬁts were greatest for the patientswith diminished left ventric-
ular ejection fraction (LVEF).
The characteristics of the cardiac surgery setting differ from the
conditions in the context of levosimendan use in patients with acute
heart failure. Factors that apply to cardiology patients are frequently
not the same as those that apply perioperatively. Suspension of standard
therapy in the perioperative period, use of cardiopulmonary bypass
(CPB), blood loss, rapid intravascular and extravascular ﬂuid shifts, and
systemic inﬂammatory response syndrome can affect the impact of
levosimendan treatment. This indicated the need for speciﬁc handling of
levosimendan in cardiac surgery patients with respect to the deﬁni-
tion of indications, modality of administration, and management of
side effects.
Therefore, 27 experts from 18 countries convened to review the liter-
ature and to agree upon a series of recommendations. The panellists are
all recognized specialists in the ﬁelds of cardiothoracic anaesthesiology,
cardiothoracic surgery, cardiology, cardiovascular pharmacology, and
intensive care medicine. They extensively discussed the preoperative
use of levosimendan, and formulated a list of questions. Thereafter, the
panellists received a questionnaire and responded through internetvoting. The results are presented here, together with the evidence of the
pharmacology of levosimendan, and a discussion of the available clinical
data.
2. Pharmacology of the cardioprotective effects of levosimendan
Levosimendan is characterised by a triple mechanism of action
[8]; i.e., it acts via calcium-dependent binding to cardiac troponin
C, and opens the KATP channels on smooth muscle cells in the vascu-
lature, and in cardiac mitochondria. This binding of levosimendan to
troponin C and the opening of KATP channels on smooth muscle cells
in the vessels result in its inotropic and vasodilatory effects, respec-
tively, while the opening of KATP channels in cardiac mitochondria is
believed to be a cardioprotective pathway [15]. The deﬁnition of
cardioprotection, however, is very broad, and it can be divided
into at least two categories of effects: short-term and long-term
cardioprotection. Short-term cardioprotection encompasses effects
such as preconditioning, postconditioning, and anti-stunning, as
well as anti-ischaemic effects. Long-term cardioprotection, on the
other hand, is often referred to as having anti-remodelling, anti-
apoptotic and anti-inﬂammatory effects.
2.1. Preconditioning effects of levosimendan
The opening of KATP channels in the mitochondria has a predomi-
nant role in the protection of the myocardium from ischaemia and re-
perfusion injury [16]. By attenuation of calcium accumulation in the
mitochondria and stabilisation of the mitochondrial inner membrane
permeability, KATP channel opening results in a reduction in myocardial
cell necrosis and apoptosis induced by ischaemia–reperfusion injury.
Therefore, treatment with the KATP channel opener levosimendan prior
tomyocardial ischaemiawillmimic ischaemic preconditioning. According
to ex-vivo data obtained by Toit and colleagues, levosimendan precondi-
tioning can reduce infarct size by 90% [11]. Also, when compared with
milrinone in an animal model setting, there was less mortality with
levosimendan: after occlusion and reperfusion of the coronary vessels,
70% of dogs treated with levosimendan before ischaemia–reperfu-
sion survived, as compared to 20% of those treated with milrinone
[17]. In another model, the lactate/pyruvate ratio in the ischaemic
areas was reduced with levosimendan treatment prior to induction
of ischaemia [18]. Finally, Kersten and co-workers also showed
that levosimendan has protective effects against myocardial ischae-
mia in a dog model: with levosimendan treatment, infarct size was
decreased by 50% [19].
2.2. Anti-stunning effects of levosimendan
Myocardial stunning occurs when acute myocardial ischaemia leads
to a transient impairment of the contractile function. In patients with
coronary artery disease, repeated episodes of demand ischaemia can
lead to cumulative stunning, which has been suggested to be a factor
in the development of chronic post-ischaemic left ventricular dysfunc-
tion [20].
Sonntag and co-workers demonstrated the anti-stunning effects of
levosimendan in 24 patients with acute coronary syndrome, whereby
as compared to placebo, the total number of hypokinetic segments
was signiﬁcantly decreased with levosimendan treatment [21]. In
30 patients with acute myocardial infarction who experienced myocar-
dial stunning after emergency percutaneous coronary intervention,
Fig. 1. Stroke volume (SVI) at the start of surgery (base), 15min after the end of cardiopul-
monary bypass (post-CPB), at the end of the operation (end surgery), at arrival in the
intensive care unit (T0), and 6 (T6), 12 (T12), 24 (T24), and 48 (T48) h later.
Levosimendan (□) and Milrinone (▲). Data are mean ± standard deviation. *, statistically
signiﬁcant difference between groups for P b 0.05.
Data from de Hert et al. [28].
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ly improved myocardial function, as compared to placebo [22]. In a re-
cent randomised, double-blind clinical trial with 61 patients who
developed clinical signs of heart failure within 48 h of primary
percutaneous-coronary-intervention-treated STEMI (including cardio-
genic shock), 25-h treatment with levosimendan showed signiﬁcant-
ly greater improvement in their wall motion score index from
baseline to day 5, as compared to placebo [23].
2.3. Anti-ischaemic effects of levosimendan
In a rodent model of healed myocardial infarction, Levijoki and
co-workers showed that treatment with levosimendan correlated
with decreased mortality [13]. These preclinical data were con-
ﬁrmed more recently in another study [24].
3. Pharmacokinetic and pharmacodynamic considerations
Levosimendan has a half-life for elimination of about 1 h. With-
out a loading dose, a steady-state concentration can be achieved ap-
proximately 4 h after the start of continuous levosimendan infusion.
After the infusion, the levosimendan serum concentrations decrease
relatively rapidly. Levosimendan, however, has an active circulating
metabolite known as OR-1896, which has a half-life for elimination
of approximately 80 h [25]. In patients with heart failure, OR-1896
reaches its peak level approximately 2 days after the end of a 24-h
infusion of levosimendan, and is removed from the circulation
over the following 2 weeks [25]. Lilleberg and colleagues showed
that levosimendan treatment of patients with heart failure for 24 h
improves cardiac output and reduces pulmonary capillary wedge
pressure (PCWP) for at least 1 week [26]. A reduction in the N-
terminal-pro-atrial natriuretic peptide levels was observed for at
least 2 weeks.
In the cardiac surgery setting, OR-1896 can be found in the plasma,
but compared to heart failure patients, its formation occurs at a slower
pace [27]. Peak levels are observed 5 days to 6 days after the discontin-
uation of levosimendan infusion. This is probably due to preoperative
fasting and to the use of broad-spectrum antibiotics in cardiac surgery.
Clinical data obtained in patients with low preoperative LVEF (≤30%)
scheduled for elective cardiac surgery indicated a prolonged effect of
levosimendan on the stroke volume index [28]. The patients received
either levosimendan 0.1 μg/kg/min infusion for 19 h or milrinone
0.5 μg/kg/min infusion for 83 h. Within the ﬁrst few hours, the effects
on stroke volume index were comparable in both groups, but a more
pronounced effect was seen with levosimendan during the follow-up
period for up to 48 h, even though levosimendan treatment had already
been discontinued (Fig. 1).
By overviewing the pharmacodynamic and pharmacokinetic
properties of levosimendan, it becomes clear that its preoperative,
or alternatively perioperative, use might have effects that are very
different. Indeed, in the preoperative settings, the cardioprotective
effects of levosimendan would have a major role along with its hae-
modynamic effects (inotropic and vasodilatory), and levosimendanmight
be further differentiated fromother inodilatory, haemodynamically active
or vasoactive drugs.
4. Published data on the preoperative and perioperative use
of levosimendan
In the systematic analysis of the literature, the data sources used
were PubMed, Index Medicus, Excerpta Medica, Reference Update,
BIOSIS, and Science Citation Index. The pertinent studies were inde-
pendently identiﬁed by two trained investigators (updated March
27, 2014). The papers and abstracts found by searching ([levosimendan
OR Simdax] and [surgery OR bypass OR valve OR CABG OR anest*])
were selected according to the PRISMA search and the inclusionstrategy described in Fig. 2, and grouped according to the timing of
the use of levosimendan and the type of intervention, as in the fol-
lowing sections (see Table 1).4.1. Preoperative use in on-pump cardiac surgery
4.1.1. Coronary artery bypass grafting surgery
In a randomised, double-blind, placebo-controlled trial by Tritapepe
and coworkers, levosimendan 24 μg/kg infusion for 10 min before initi-
ation of coronary artery bypass grafting (CABG) led to signiﬁcant reduc-
tions in tracheal intubation time, length of Intensive CareUnit (ICU) stay
(P b 0.01 for both), and the proportion of patients requiring inotropic
support for N12 h (3.8% vs. 18.0% for placebo; P = 0.021) [29]. As com-
pared to placebo, levosimendan-treated patients had signiﬁcantly lower
postoperative troponin I levels (Fig. 3) and a signiﬁcantly higher cardiac
index (P b 0.0001 each).
The preoperative use of levosimendan in high-risk patients with se-
vere left ventricular dysfunction (LVEF b25%) scheduled for CABG was
assessed in a randomised, placebo-controlled trial [30]. Levosimendan
was started 24 h before surgery, with a loading dose of 10 μg/kg infusion
for 1 h thatwas followed by continuous infusion of 0.1 μg/kg/min infusion
for 23 h. Overall, 252 patients participated in the study. Levosimendan re-
duced mortality compared to placebo (3.9% vs. 12.8%; P b 0.05), and
decreased the incidence of LCOS (7.1% vs. 20.8%; P b 0.05) and of
complicated weaning from CPB (2.4% vs. 9.6%; P b 0.05). The
levosimendan-treated group also showed lower requirement for
other inotropes compared to placebo (7.9% vs. 58.4%; P b 0.05),
and for vasopressors (14.2% vs. 45.6%; P b 0.05), and lower use of
an intra-aortic balloon pump (6.3% vs. 30.4%; P b 0.05).4.1.2. CABG and aortic valve surgery
In 24 patients undergoing combined aortic valve and CABG surgery,
preoperative levosimendan 12 μg/kg infusion for 10 min followed by a
continuous infusion of levosimendan 0.2 μg/kg/min infusion for
24 h signiﬁcantly improved cardiac index and stroke volume index
throughout the 4-day postoperative period (P b 0.05) [31]. The LVEF
was maintained in the levosimendan group, whereas it decreased in the
control group.
Fig. 2. PRISMA ﬂow diagram [71] for search and inclusion of scientiﬁc information into systematic reviews applied to the search ((levosimendan OR Simdax) and (surgery OR bypass OR
valve OR CABG OR anest*)) updated March 27, 2014.
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4.2.1. CABG surgery
A randomised, double-blind trial assessed the effects of levosimendan
on haemodynamics, coronary blood ﬂow, and myocardial substrate use
early after CABG [32]. Two dose schedules (levosimendan 8 μg/kg or
24 μg/kg as 5-min infusions after CABG)were comparedwith placebo. Al-
though levosimendan improved cardiac performance by increasing cardi-
ac output and coronary sinus blood ﬂow, it did not increase myocardial
oxygen consumption or change myocardial substrate use.
De Hert and co-workers conducted a randomised study with 30 pa-
tients scheduled for CABGwith preoperative LVEF≤30% [28]. In addition
to dobutamine, the patients received either milrinone 0.5 μg/kg/min
infusion or levosimendan 0.1 μg/kg/min infusion immediately after the
release of the aortic crossclamp. These infusions were continued until
weaning from inotropic support. The stroke volume index declined 12 hFig. 3. Cardiac troponin I concentrations (mean ±95% conﬁdence intervals) in the
levosimendan (□) and placebo (▲) groups before surgery (baseline), on arrival in the
intensive care unit (0), and after 6, 24, and 48 h.
Data from Tritapepe et al. [29].after surgery in the milrinone group, but not in the levosimendan group
(P b 0.05) despite similar ﬁlling pressures. Total dose, duration of
inotropic drug administration, and norepinephrine doses were sig-
niﬁcantly lower with levosimendan (P b 0.05). Moreover, the dura-
tion of tracheal intubation was shorter in the levosimendan-treated
group (P = 0.008).
Levin and colleagues compared levosimendan (10 μg/kg as 1 h infu-
sion followed by 0.1 μg/kg/min infusion for 24 h) and dobutamine
(starting dose, 5 μg/kg/min infusion) in a randomised trial with 137 pa-
tients with LCOS after surgery [33]. Patients treated with levosimendan
experienced signiﬁcant beneﬁts in the postoperative period, with im-
provements in haemodynamic parameters with levosimendan that
were greater and occurred earlier than with dobutamine. PostoperativeFig. 4. Need for additional inotropic support in patients with LCOS after cardiac surgery in
the study by Levin and colleagues [33], with treatment with levosimendan (white bars)
and dobutamine (black bars). *, statistically signiﬁcant difference between groups for
P b 0.05.
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mine (8.7% vs. 25%; P b 0.05), as was the need for vasopressors, second
or third inotropes, and intraaortic balloon pump (IABP) use (Fig. 4).
In the randomised, double-blind LEWE study, levosimendan facili-
tated weaning from CPB and reduced the need for additional inotropic
or mechanical circulatory support in patients with impaired LVEF
(≤50%) undergoing CABG [27]. Sixty patients received either
levosimendan as a 12 μg/kg bolus followed by 0.2 μg/kg/min infu-
sion, or placebo, started immediately after the induction of anaesthesia.
Levosimendan signiﬁcantly facilitated primaryweaning fromCPB as com-
paredwith placebo (P=0.002; Fig. 5). Four patients in the placebo group
even failed the secondweaning and had to be supported by IABP, as com-
pared with none in the levosimendan group (P = 0.112).
4.2.2. CABG and valve surgery
In a randomised, placebo-controlled trial, Lahtinen and colleagues
demonstrated that levosimendan treatment diminished the incidence
of heart failure after heart valve or combined heart valve and CABG sur-
gery [34]. Levosimendan 24 μg/kg over 30 min of infusion followed by
0.2 μg/kg/min infusion for 24 h, or placebo, was administered after in-
duction of anaesthesia. Fifteen percent of patients in the levosimendan
group and 58% in the placebo group experienced postoperative heart
failure (P b 0.001). Accordingly, the use of rescue inotropes and IABP
was signiﬁcantly less in the interventional arm (P = 0.005 and P =
0.018, respectively). The level of the myocardial fraction of creatine ki-
nase, which is indicative of myocardial damage, was lower in the
levosimendan group on the ﬁrst postoperative day, compared to placebo
(P = 0.011). In contrast, the use of vasopressors was signiﬁcantly higher
in the levosimendan armdue to arterial hypotension (P b 0.001). Hospital
mortality rates and 6-month mortality rates were similar in both groups.
4.2.3. Aortic valve surgery
Twenty-four patients with severe aortic stenosis and left ventric-
ular hypertrophy undergoing aortic valve surgery were included in a
randomised, double-blind trial by Järvelä and co-workers [35]. In
patients receiving a 24-h infusion of levosimendan 0.2 μg/kg/min
starting after the induction of anaesthesia, LVEF was maintained,
while it dropped in the placebo-treated group. This difference was
not signiﬁcant, however.
Jörgensen and others found that in addition to its inotropic effects,
levosimendan can have a positive lusitropic effect in patients with left
ventricular hypertrophy, as it shortened isovolumic relaxation time
and improved left ventricular ﬁlling [36]. This randomised, blindedFig. 5. Weaning from cardiopulmonary bypass (CPB). First weaning attempt with
levosimendan (white bars) and placebo (black bars). Epinephrine added to second
weaning attempt. *, Weaning failure led to use of intra-aortic balloon pump.
Data from Eriksson et al. [27].study compared two dose schedules (0.1 μg/kg/min and 0.2 μg/kg/min
infusions for 20 min, after initial loading dose of 12 μg/kg infusion for
10 min) with placebo in 23 patients after aortic valve replacement for
aortic stenosis. Levosimendan treatment showed a dose-dependent in-
crease in cardiac output (+28%; P b 0.001) and stroke volume (+26%;
P b 0.001), and a decrease in systemic vascular resistance (−22%;
P b 0.001). There was a trend towards an increase in LVEF (12%; P =
0.058). After the administration of levosimendan, as compared to place-
bo, isovolumic relaxation time decreased (−3%; P b 0.001), as did the
deceleration slope of early diastolic ﬁlling (−45%; P b 0.01). Both peak
early diastolic ﬁlling velocity (16%, P b 0.01) and peak late diastolic ﬁll-
ing velocity (15%; P b 0.001) increased signiﬁcantly.
4.2.4. CABG and mitral valve surgery
A case-matched study compared levosimendan with the use of an
IABP in heart failure patients undergoing elective CABG without or
with concomitant mitral valve surgery [37]. Eleven patients received
levosimendan infusion at a dose of 0.1 μg/kg/min for 24 h,while another
11 patients received preoperative IABP. The length of stay at the ICUwas
signiﬁcantly reduced in the levosimendan-treated group, compared to
IABP use (2.5 vs. 5 days; P = 0.01).
4.2.5. Mitral valve surgery
Gandham and co-workers compared the use of levosimendan
0.1 μg/kg/min infusion with dobutamine 5 μg/kg/min infusion for
weaning from CPB in 60 patients whowere undergoingmitral valve re-
pair or replacement for severemitral stenosis [38]. The patients who re-
ceived levosimendan showed greater reductions in systemic vascular
resistance index, central venous pressure, and mean arterial pressure,
compared to dobutamine. The requirement of inotropes and vasocon-
strictors was increased in the levosimendan-treated group. Compared
to dobutamine, there was a statistically signiﬁcant increase in cardiac
index with levosimendan, even 12 h after discontinuation.
4.3. Off-pump cardiac surgery
Several studies have tested the hypothesis that levosimendan treat-
ment is associated with beneﬁcial haemodynamic effects during and
after off-pump CABG in patients with good preoperative left ventricular
function. A randomised, four-times-masked, controlled study investi-
gated levosimendan at two dose schedules: low dose (12 μg/kg) and
high dose (24 μg/kg) as 10 min infusions [39]. These treatments were
administrated 20 min before the start of the surgery. Compared to pla-
cebo, signiﬁcant increases in cardiac output and LVEF occurred after
both the high-dose (P b 0.001 and P = 0.006, respectively) and the
low-dose (P = 0.001 and P = 0.002, respectively) treatments. Both
levosimendan doses produced signiﬁcant increases in stroke volume
and decreases in systemic vascular resistance.
In a double-blind randomised trial, 24 patients received either place-
bo or levosimendan at a dose of 12 μg/kg as an infusion for 15 min be-
fore CABG [40]. At 10 min and 60 min post-infusion, the cardiac index
and the LVEF were signiﬁcantly higher with levosimendan than with
placebo (P = 0.018 each). The stroke volume index was signiﬁcantly
higher for levosimendan at 10 min (P = 0.018), but not at 60 min
(P = 0.063).
Kodalli and colleagues compared levosimendan 0.1 μg/kg/min infu-
sion and placebo after induction of general anaesthesia in a double-
blind manner [41]. In patients receiving levosimendan, compared to
placebo, the cardiac index was signiﬁcantly higher and the systemic
vascular resistance index was signiﬁcantly lower at 6, 12, 18 and 24 h
after CABG. No improvements were noted in terms of duration of venti-
lation or ICU length of stay.
The double-blind, randomised trial by Shah and colleagues tested
preoperatively administered levosimendan 200 μg/kg infusion for 24 h
against placebo for off-pump CABG in 50 patients with left ventricular
dysfunction (LVEF b30%) [42]. As compared to the control group, the
328 W. Toller et al. / International Journal of Cardiology 184 (2015) 323–336levosimendan-treated patients had higher cardiac index and PCWPdur-
ing the operative and early postoperative periods. Also, requirements
for inotropes, IABP and CPB support were lower for levosimendan, and
both ICU and hospital length of stay were reduced.
4.4. Effects of levosimendan on kidney function
As renal dysfunction is an important complication of cardiac surgery,
several trials have investigated the potential renal beneﬁts mediated by
levosimendan. In a randomised, placebo-controlled study, levosimendan
signiﬁcantly improved renal parameters after cardiac surgery with CPB
[43]. Levosimendan was applied as a 0.1 μg/kg/min infusion for 1 h after
a loading dose of a 12 μg/kg infusion. When compared to placebo, this
treatment caused a signiﬁcant 12% increase in renal blood ﬂow, and a sig-
niﬁcant 21% increase in glomerular ﬁltration rate, whereas renal vascular
resistance decreased signiﬁcantly by 18%. There were no signiﬁcant
changes in ﬁltration fraction, renal oxygen consumption, or renal oxygen
extraction. These effects clearly differed from those of dopamine, which
also increased renal blood ﬂow, but did not increase the glomerular ﬁltra-
tion rate.
Baysal and co-workers compared levosimendan (6 μg/kg infusion
after removal of the aortic cross-clamp, followed by 24-h infusion of
0.1 μg/kg/min) with placebo in addition to standard inotropic therapy
[44]. The cohort consisted of 128 patients with LVEF ≤45% who were
undergoing mitral valve surgery. Compared with the group of pa-
tients who received only standard inotropic therapy, the addition
of levosimendan improved postoperative renal clearance on days 1
and 3. At these time points, serum creatinine levels were lower and the
estimated glomerular ﬁltration rates were higher than in the control
arm. There was a trend in favour of levosimendan regarding the need
for renal replacement therapy.
A meta-analysis by Harrison and colleagues also highlighted the
beneﬁcial effects of perioperative levosimendan on renal function, as it
showed signiﬁcant reductions in the need for dialysis in levosimendan-
treated patients (P = 0.003) [14]. A consensus paper on the overall
renal effects of levosimendan appeared also recently in the literature [45].
4.5. Effects of levosimendan on hepatic function
Liver dysfunction due to low cardiac output after cardiac surgery is as-
sociated with poor prognosis. A randomised controlled study by Alvarez
and colleagues compared the effects of dobutamine and levosimendan
on hepatic blood ﬂow in patients with low cardiac output after cardiac
surgery [46]. A total of 25 patients were randomised to receive either
levosimendan 12 μg/kg infusion for 15 min followed by 0.2 μg/kg/min
infusion for 24 h, or dobutamine 7.5 μg/kg/min infusion for 24 h. As com-
pared to dobutamine, levosimendan improved systemic and hepatic
haemodynamics (cardiac index, portal vein ﬂow, pulsatility index) at
24 h and 48 h. They also noted that levosimendan can be considered as
a liver vasodilator that improves hepatic blood ﬂow through both the
hepatic artery and the portal venous system. In contrast, dobutamine
treatment only affected portal venous blood ﬂow.
4.6. Effects of levosimendan on right heart function
The efﬁcacy of levosimendan in increasing right ventricular contrac-
tility and reducing right ventricular afterload has been demonstrated in
heart failure, cardiogenic shock related to acute myocardial infarction,
and septic shock (for review, see Nieminen et al. [47]). Levosimendan
also proved to be beneﬁcial in patients with preoperative right ventric-
ular dysfunctionwhowere undergoing implantation of a left ventricular
assist device [48]. Similarly, in a small retrospective study, Theiss
and co-workers showed superior twelve-month survival compared
to INTERMACS registry data in patients with right ventricular dys-
function treated with levosimendan before left ventricular assist
device implantation [49]. Finally, in a pilot study in patients withlow-cardiac-output heart failure after cardiac surgery, Labriola and
co-workers administered levosimendan and observed improved car-
diac index and PCWP. At the same time, themean pulmonary artery pres-
sure and right arterial pressure decreased by 13% (P b 0.001) and 25%
(P b 0.001), respectively [50].
5. Pharmaco-economic considerations
Health- and pharmaco-economic analyses on the use of levosimendan
in acute decompensated heart failure have shown that its use is cost-
effective [51-53]. We did not ﬁnd in the literature, however, systematic
health economic studies on the use of levosimendan in cardiac surgery.
Fromananalysis of the available data, it appeared tous that levosimendan
positively affects themajor elementswhich are likely to increase the costs
of treatment in cardiac surgery: (1) the ICU stay has been reported to be
shorter in several levosimendan studies [29,30]; (2) there is less need for
IABP (both the actual number of the patients and the duration) [28,30,33,
34,54]; and (3) there is less need for renal replacement therapy in
levosimendan treated patients [14,30,33,44]. As it regard the concomitant
use of other vasoactive drug, a higher need for vasopressors when using
levosimendan is compensated by a lower need of inotropes. Overall, the
expectation is that levosimendan treatment in cardiac surgery would be
cost-effective [55], despite its higher cost compared to dobutamine.
6. Ongoing trials
A number of European trials are currently assessing the periopera-
tive use of levosimendan (see Table 3). The LICORN study is investigat-
ing the efﬁcacy of preoperative levosimendan in patients with LVEF
≤40% undergoing CABG with or without valve replacement under
CPB (study number P110138, France). The primary endpoint of this
placebo-controlled study is a composite that includes the use of inotro-
pic agents beyond 24 h after the end of study drug infusion, or the need
of postoperative mechanical assist devices (IABP or others), or the im-
possibility towean the patients from circulatory support if theywere al-
ready in use preoperatively, or the need for renal replacement therapy.
Secondary endpoints include mortality at days 28 and 180, each item of
the primary endpoint separately, and length of ICU and hospital stays.
Levosimendan is being administered as a 0.1 μg/kg/min infusion for
24 h and is started at the time of anaesthesia induction, without
bolus application. The study population will include 340 patients.
A recently completed (but not yet published) double-blind study by
Argyriadou and co-workerswas aimed at conﬁrmation of the beneﬁts of
preoperative levosimendan in patients with left ventricular dysfunction
(LVEF≤40%) routinely scheduled for CABG (NCT01318460). Thirty-two
patients were randomised to either levosimendan 0.1 μg/kg/min infu-
sion for 24 h before surgery, or placebo. A preliminary analysis of the
data favoured levosimendan treatment to a signiﬁcant degree: while
the placebo group showed no signiﬁcant difference between preop-
erative and postoperative LVEF, LVEF increased signiﬁcantly in the
levosimendan group on the 7th postoperative day. Moreover, cardi-
ac index, tissue perfusion, and PCWP were signiﬁcantly improved in
the experimental arm.
InNorth America, a randomised, placebo-controlled, phase III pivotal
trial in high-risk patients undergoing CABG (LVEF ≤25%) and/or mitral
or aortic valve surgery (LVEF≤35%) started in the third quarter of 2014
(NCT02025621). A total of 760 patients in 50 cardiac surgery centres
across North America will receive either levosimendan 0.2 μg/kg/min
infusion for 1 h followed by 0.1 μg/kg/min infusion for 23 h, or placebo.
Infusion will be started before surgery. Co-primary endpoints comprise
death, use of mechanical assist devices (IABP, left ventricular assist
device), myocardial infarction, and dialysis. Secondary endpoints in-
clude postoperative duration of stay at the ICU or coronary care unit,
and incidence of LCOS. The safety endpoint is the all-cause mortality
by day 90.
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cardiac surgery (HSR-LEVO) is comparing levosimendan to placebo on
mortality andmorbidity in 1000 patients at risk of LCOS, and this is cur-
rently recruiting (NCT00994825). An interim analysis of the data is
planned after the ﬁrst 250 patients.
7. Composition of the panel and mode of agreement on
the recommendations
The panellists were 27 experts from 18 countries (Austria, Belgium,
Croatia, Czech Republic, Finland, France, Germany, Greece, Hungary,Table 1
Studies on preoperative and perioperative use of levosimendan.
From PubMed.
First author Title Type of study/comparator N
pa
On-pump preoperative
CABG
Tritapepe
[29]
Levosimendan pre-treatment
improves outcomes in patients
undergoing CABG
Randomised, double-blind/vs.
placebo
10
Levin [30] Preoperative levosimendan
decreases mortality and the
development of low cardiac
output in high-risk patients with
severe left ventricular dysfunction
undergoing CABG with
cardiopulmonary bypass (EF
b25%)
Randomised/vs. placebo 25
12
Dogan [56] Levosimendan use decreases atrial
ﬁbrillation in patients after CABG:
a pilot study
Prospective, randomised/vs.
placebo
20
10
Eris [55] Preoperative uses of levosimendan
in patients undergoing CABG
(LVEF b30%)
Retrospective/levosimendan
infusion applied 12 h before
operation (G1), after induction
of anaesthesia (G2), during the
pump removal (G3) and non-LS
control (G4)
40
CABG + aortic
valve
Leppikangas
[31]
Preoperative levosimendan
infusion in combined aortic valve
and coronary bypass surgery
Randomised/vs. placebo 24
On-pump perioperative
CABG
Lilleberg
[32]
Effects of levosimendan on
haemodynamics, coronary blood
ﬂow, and myocardial substrate use
early after CABG
Randomised, double-blind/vs.
placebo
23Israel, Italy, Russia, Slovenia, Spain, Sweden, Switzerland, the U.K., and
the U.S.A.), all recognized specialists in the ﬁelds of cardiothoracic an-
aesthesiology, cardiothoracic surgery, cardiology, cardiovascular phar-
macology, and intensive care medicine. They were invited to join the
panel by the chairmen (WT, MH, FG), on the basis of their experi-
ence with preoperative and perioperative use of levosimendan doc-
umented in the literature.
After discussing the available evidence on preoperative and intra-
operative use of levosimendan, the panel found that the rationale for
preoperative use of levosimendan is profoundly different from that
for its perioperative (or intraoperative) use. Indeed, intraoperatively,umber of
tients
Levosimendan dosing/timing of
dose
Results
6 (2 × 53) 24 μg/kg for 10 min infusion
before the initiation of bypass
Signiﬁcant reductions in tracheal
intubation time, length of ICU stay
and number of patients requiring
inotropic support for N12 h with
levosimendan. Signiﬁcantly lower
postoperative troponin I
concentrations and higher cardiac
index
3 (127 vs.
5)
Loading dose (10 μg/kg), 23 h
infusion (0.1 μg/kg/min)
Levosimendan group had a lower
incidence of complicated weaning
from CPB (2.4% vs. 9.6%; P b 0.05),
decreased mortality (3.9% vs.
12.8%; P b 0.05) and a lower
incidence of LCOS (7.1% vs. 20.8%;
P b 0.05) compared with the
control group, lower requirement
for inotropes (7.9% vs. 58.4%; P b
0.05), vasopressors (14.2% vs.
45.6%; P b 0.05) and intra-aortic
balloon pumps (6.3% vs. 30.4%; P b
0.05)
0 (2 ×
0)
Levosimendan started 6 h before
operation. In the operating room,
levosimendan continued at 24
μg/kg as a slow drip through the
central venous catheter and
stopped before the initiation of
CPB. During the rewarming period,
levosimendan was started again
via the central vein with the same
dose.
Postoperative AF in levosimendan
group was reduced in patients
with poor left ventricle function
after CABG operations. C-reactive
protein was higher
postoperatively in the control
(4 × 10) (0.2 μg/kg/min infusion) Increase of LVEF; infusion of
levosimendan 12 h before surgery
produced less myocardial damage
(2 × 12) 12 μg bolus for 10 min followed by
0.2 μg/kg/min infusion for 24 h;
treatment was started on the day
before surgery
Higher cardiac index and stroke
volume index with levosimendan
for the 4-day postoperative period
(P b 0.05). LVEF maintained (the
control group showed a decrease)
(8, 8, 7) Two dose schedules: 8 μg/kg or 24
μg/kg infusions after CABP
Heart rate increased signiﬁcantly
after the higher dose; cardiac
output increased signiﬁcantly
after both doses, while systemic
and pulmonary vascular
resistance decreased signiﬁcantly.
Coronary sinus blood ﬂow
increased after both doses.
(continued on next page)
Table 1 (continued)
First author Title Type of study/comparator Number of
patients
Levosimendan dosing/timing of
dose
Results
Nijhawan
[57]
Levosimendan enhances cardiac
performance after
cardiopulmonary bypass: a
prospective, randomised
placebo-controlled trial
Prospective, randomised,
double-blind/vs. placebo
18 (3 × 6) Two dose schedules: 18 (low
dose) or 36 (high dose) μg/kg
bolus and 0.2 (low dose) or 0.3
(high dose) μg/kg/min infusion.
Administration started before
separation from CPB and was
continued for 6 h after CPB.
Placebo patients experienced
signiﬁcant increases in heart rate
and decreases in systemic vascular
resistance 15 min after CPB, as well
as later increases in mean arterial
pressure and cardiac output and
decreases in stroke volume and
pulmonary vascular resistance.
Heart rate was greater in patients
receiving high-dose but not
low-dose levosimendan versus
placebo immediately after CPB.
Mean arterial pressure also was
lower in patients treated with either
levosimendan dose compared with
placebo after CPB. Levosimendan
increased cardiac output and
decreased systemic vascular
resistance.
Alvarez [58] Hemodynamic effects of
levosimendan following cardiac
surgery
Randomised/vs. dobutamine 30 (2 × 15) Loading dose 18 μg/kg in 15–20
min infusion followed by 24-h
infusion of 0.2 μg/kg/min
Heart rate and cardiac index
increased in the levosimendan
group only (P b 0.05). MAP,
systemic and pulmonary vascular
resistance decreased signiﬁcantly in
the levosimendan group (P b 0.05)
only.
Alvarez [59] Hemodynamic effects of
levosimendan compared with
dobutamine in patients with low
cardiac output after cardiac
surgery
Randomised/vs. dobutamine 41 (20 vs. 21) Loading dose 12 μg/kg infusion
followed by 24-h infusion of 0.2
μg/kg/min
Levosimendan improved cardiac
index more than dobutamine (2.4
[0.2] vs. 2.9 [0.3] l/min/m2,
respectively, at 24 h; P b 0.05) and
reduces systemic and pulmonary
vascular resistance, decreases
systemic arterial, pulmonary
arterial, pulmonary capillary wedge,
and central venous pressure
Al-Shawaf
[60]
Levosimendan or milrinone in the
type 2 diabetic patient with low
LVEF undergoing elective coronary
artery surgery
Randomised/vs milrinone 50
μg/kg for 10 min followed by 0.3
to 0.5 μg/kg/min infusion for 24
h
30 (14 vs. 16) 12 μg/kg bolus for 10 min followed
by 0.1 to 0.2 μg/kg/min infusion
for 24 h
Signiﬁcantly higher cardiac index
and mixed venous oxygen
saturation with levosimendan;
signiﬁcantly lower pulmonary
capillary wedge pressure, systemic
vascular resistance and oxygen
extraction ratios
Akgul [54] Levosimendan for weaning from
cardiopulmonary bypass after
CABG
Prospective 15 12–24 μg/kg loading dose for 10
min infusion followed by 0.1–0.2
μg/kg/min infusion for 24 h
All patients showed evidence of
hemodynamic improvement with
the start of LS infusion, and 93.3%
were successfully weaned from CPB.
53.3% experienced signiﬁcant
increases in cardiac index and blood
pressure, leading to a lessening of
the need for catecholamine support.
De Hert [28] The effects of levosimendan in
cardiac surgery patients with poor
left ventricular function
Randomised/vs. milrinone 0.5
mg/kg/min infusion
30 (2 × 15) 0.1 mg/kg/min infusion started
immediately after the release of
the aortic crossclamp, continued
until weaning from inotropic
support.
Stroke volume declined 12 h after
surgery in the milrinone group but
not in the LS group (P b 0.05)
despite similar ﬁlling pressures.
Total dose, duration of inotropic
drug administration and
norepinephrine dose were lower
with levosimendan (P b 0.05). The
duration of tracheal intubation was
shorter with levosimendan (P =
0008). Three patients in the
milrinone group but none in the
levosimendan group died within 30
days of surgery.
Levin [33] Levosimendan gives superior
results to dobutamine in
postoperative low cardiac output
syndrome
Randomised/s. dobutamine 5
μg/kg/min infusion
137 (69 vs.
68)
10 μg/kg loading dose followed by
0.1 μg/kg/min infusion for 24 h
Improvement of hemodynamic
parameters was greater with
levosimendan and occurred earlier.
Postoperative mortality was lower
(8.7% vs. 25%; P b 0.05), as were
major postoperative complications.
The need for additional inotropic
drug treatment, vasopressor
therapy or balloon
counterpulsation was lower.
Levosimendan-treated patients
experienced shorter ICU stay.
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First author Title Type of study/comparator Number of
patients
Levosimendan dosing/timing of
dose
Results
Eriksson
[27]
Levosimendan facilitates weaning
from cardiopulmonary bypass in
patients undergoing CABG with
impaired left ventricular function
Prospective, randomised,
double-blind/vs. placebo
60 (2 × 30) 12 μg/kg bolus for 10 min followed
by 0.2 μg/kg/min infusion for 24 h;
administration was started
immediately after induction of
anaesthesia
Levosimendan signiﬁcantly
enhanced primary weaning from
CPB compared with placebo (P =
0.002). Four patients in the
placebo group failed the second
weaning and underwent IABP
compared with none in the
levosimendan group (P = 0.112).
Lomivorotov
[61]
Levosimendan versus intra-aortic
balloon pump in high-risk cardiac
surgery
Randomised/vs. preoperative
IABP
40 (2 × 20) 12 μg bolus for 10 min followed by
0.2 μg/kg/min infusion for 24 h;
treatment was started after
induction of anaesthesia.
Signiﬁcantly lower levels of
troponin I at 6 h after surgery with
levosimendan, signiﬁcantly
shorter intensive care unit stay
Lomivorotov
[62]
Levosimendan versus an
intra-aortic balloon pump in
high-risk cardiac patients
90 (3 × 30) Levosimendan caused
signiﬁcantly increased cardiac
index 5 min after CPB, at the end
of the operation, and 2 h and 4 h
after perfusion. Signiﬁcantly
lower level of troponin I 6 h after
surgery, signiﬁcantly shorter stay
at the intensive care unit
CABG + valve
Tasouli [63] Efﬁcacy and safety of
perioperative infusion of
levosimendan in patients with
compromised cardiac function
undergoing open-heart surgery:
importance of early use
Randomised: during or after
open-heart surgery
45 0.1 μg/kg min without loading
dose for 24–48 h
ICU stay and hospital stay were
signiﬁcantly decreased when
levosimendan was started in the
operating theatre already rather
than at the ICU.
Lahtinen
[34]
Levosimendan reduces heart
failure after cardiac surgery: a
prospective, randomised,
placebo-controlled trial
Prospective, randomised/vs.
placebo
200 (99 vs.
101)
24 μg/kg bolus over 30 min
followed by 0.2 μg/kg/min infusion
for 24 h
Levosimendan led to a reduced
incidence of heart failure, but was
associated with arterial
hypotension and increased
requirement of vasopressor
agents postoperatively.
Järvelä [35] Levosimendan in aortic valve
surgery: cardiac performance and
recovery
Prospective, randomised,
double-blind/vs. placebo
24 (2 × 12) 0.2 μg/kg/min infusion for 24 h
beginning after the induction of
anaesthesia
LVEF was maintained with
levosimendan but dropped with
placebo (n.s.).
Jörgensen
[36]
Effects of levosimendan on left
ventricular relaxation and early
ﬁlling at maintained preload and
afterload conditions after aortic
valve replacement for aortic
stenosis
Prospective, randomised,
blinded/vs. placebo
23 (12 vs. 11) Two dose schedules: 0.1 or 0.2
μg/kg/min infusion for 20 min
after initial loading doses of 12
μg/kg infusion for 10 min
Levosimendan gave rise to
dose-dependent increases in
cardiac output (28%; P b 0.001)
and stroke volume (26%; P b
0.001) as well as decreases in
systemic vascular resistance
(−22%; P b 0.001). Trend for an
increase in LVEF. Decreases in
isovolumic relaxation time and
deceleration slope of early
diastolic ﬁlling; increased peak
early diastolic ﬁlling velocity
and peak late diastolic ﬁlling
velocity
CABG + mitral
Severi [37] Levosimendan versus intra-aortic
balloon pump in high-risk cardiac
surgery patients
Case-matched/vs. preoperative
IABP
22 (2 × 11) 0.1 μg/kg/min infusion for 24 h Shorter duration of ICU stay
with levosimendan (2.5 vs. 5
days; P = 0.01)
Mitral
Gandham
[38]
A comparison of hemodynamic
effects of levosimendan and
dobutamine in patients
undergoing mitral valve
repair/replacement for severe
mitral stenosis
Randomised/vs. dobutamine 5
μg/kg/min infusion
60 (2 × 30) 0.1 μg/kg/min infusion while
weaning off CPB
Increased vasodilation and lesser
inotropic activity with
levosimendan, statistically
signiﬁcant increase in cardiac
index even after 12 h of
discontinuation. Increased
requirement of inotropes and
vasoconstrictors
Off-pump
Barisin [39] Levosimendan in off-pump
coronary artery bypass: a
four-times masked controlled
study
Randomised, four-times
masked/vs. placebo
31 (11, 10,
10)
Two dose schedules: low dose (12
μg/kg), high dose (24 μg/kg) over
10 min; treatment was given 20
min before start of surgery
Signiﬁcant increases in cardiac
output and LVEF occurred after
high-dose (P b 0.001; P = 0.006)
and low-dose levosimendan (P =
0.001; P = 0.002). Both
levosimendan doses produced
signiﬁcant increased stroke
volume and decreased systemic
vascular resistance.
(continued on next page)
331W. Toller et al. / International Journal of Cardiology 184 (2015) 323–336
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First author Title Type of study/comparator Number of
patients
Levosimendan dosing/timing of
dose
Results
Husedzinović
[40]
Levosimendan as a new strategy
during off-pump CABG:
double-blind randomised
placebo-controlled trial
Randomised, double-blind/vs.
placebo
24 (2 × 12) 12 μg/kg bolus for 15 min before
surgery
Cardiac index and LVEF were
signiﬁcantly higher 10 min and 60
min (P = 0.018 for all) after
levosimendan administration. After
60 min, cardiac index increased
from 2.18 to 2.84 l/min/m2. Stroke
volume index was signiﬁcantly
higher at 10 min (P = 0.018), but
not at 60 min (P = 0.063).
Kodalli [41] Effect of levosimendan on
hemodynamic changes in patients
undergoing off-pump CABG: a
randomised controlled study
Randomised/vs. placebo 30 (2 × 15) 0.1 μg/kg/min infusion during
surgery
Signiﬁcant increase of cardiac
index and signiﬁcant decrease of
vascular resistance index with
levosimendan at 6, 12, 18 and 24
h after surgery. No outcome
beneﬁt in terms of duration of
ventilation or ICU stay
Shah [42] Levosimendan during off-pump
CABG in patients with LV
dysfunction
Randomised double-blind/vs.
placebo
50 (2 × 25) 200 μg/kg infusion in 24 h Levosimendan increased cardiac
index during operative and early
operative period.
Levosimendan-treated patients
had less requirement for
inotropes, IABP, CPN, ICU stay and
hospital stay.
Mainly describing renal function
Ristikankare
[64]
Effects of levosimendan on renal
function in patients undergoing
coronary artery surgery
Prospective, randomised,
double-blind substudy/vs.
placebo
60 (2 × 30) 12 μg/kg bolus for 10 min followed
by 0.2 μg/kg/min infusion for the
next 23 h and 50 min
No signiﬁcant changes in plasma
creatinine, serum cystatin C, and
urine NAG at any of the measuring
points
Bragadottir
[43]
Effects of levosimendan on
glomerular ﬁltration rate, renal
blood ﬂow, and renal oxygenation
after cardiac surgery with
cardiopulmonary bypass: a
randomised placebo-controlled
study
Prospective, randomised/vs.
placebo
30 (2 × 15) 0.1 μg/kg/min infusion for 1 h after
a loading dose of 12 μg/kg
Increases in cardiac index (22%),
stroke volume index (15%) and
heart rate (7%) with
levosimendan over placebo,
decreased systemic vascular
resistance index (21%). Signiﬁcant
increases in renal blood ﬂow (12%,
P b 0.05) and glomerular ﬁltration
rate (21%, P b 0.05), decreased renal
vascular resistance (18%, P b 0.05).
Baysal [44] Levosimendan improves renal
outcome in cardiac surgery: a
randomised trial
Randomised/vs. placebo on top
of standard inotropic therapy
280 (2 × 64) Loading dose (6 μg/kg) after removal
aortic cross-clamp, 24 h infusion
(0.1 μg/kg/min) in addition to
standard inotropic therapy
Valve surgery improved
immediate postoperative renal
function (eGFR) and reduced need
for renal replacement therapy.
Mainly describing liver function
Alvarez [46] A comparison of dobutamine and
levosimendan on hepatic blood
ﬂow in patients with a low cardiac
output state after cardiac surgery:
a randomised controlled study
Randomised/vs. dobutamine 7.5
μg/kg/min infusion for 24 h
25 Levosimendan (12 μg/kg infusion)
over 15 min + infusion of 0.2
μg/kg/min for 24 h
The systemic and hepatic
haemodynamics at 24 h and 48 h
were all better after levosimendan
than dobutamine. Levosimendan
is selective liver vasodilator and
improves hepatic blood ﬂow
through both the hepatic artery
and portal venous system.
Mainly describing right heart function
Sponga [48] Preoperative treatment with
levosimendan in candidates for
mechanical circulatory support
Consecutive 21 Levosimendan 0.1 to 0.2
mg/kg/min infusion for a
maximum of 48 h without bolus
Levosimendan improves
preoperative hemodynamic
conditions in LVAD candidates
with borderline right ventricular
function.
Labriola [50] Haemodynamic effects of
levosimendan in patients with
low-output heart failure after
cardiac surgery
Consecutive 11 Levosimendan 12 μg/kg over 10
min, followed by a continuous
infusion of 0.1 μg/kg/min for 12 h
Levosimendan improves cardiac
index, and reduces PCWP, mean
pulmonary artery pressure and
right arterial pressure.
Theiss [49] Preconditioning with
levosimendan before implantation
of left ventricular assist devices
Retrospective, consecutive 9 Levosimendan continuous
infusion of 0.1 μg/kg/min for 24 h
Levosimendan improved clinical
outcome and survival when used
as pretreatment in patients with
right heart insufﬁciency prior to
LVAD implantation.
332 W. Toller et al. / International Journal of Cardiology 184 (2015) 323–336levosimendan is primarily used for its inodilatory effects, which
can be achieved without any negative impact on myocardial oxygen
balance. In contrast, in the preoperative setting, levosimendan is
used also in an attempt to provide patient beneﬁt through itscardioprotective properties that come into effect later during the in-
traoperative period.
For the sake of clarity, the panel decided to discuss these two appli-
cations of levosimendan separately. The panel recognized that theuse of
Table 2
Opinions of the 24 European experts on the preoperative use of levosimendan in cardiac surgery.
1. Type of patient
Which type of cardiac surgical patients would you suggest to give preoperative 
levosimendan? Definitely yes
Neutral opinion/
no direct experience/no answer Definitely no
CABG with low LVEF 100% 0% 0%
CABG plus mitral valve surgery 71% 29% 0%
Mitral valve replacement plus aortic valve replacement 29% 71% 0%
Mitral valve replacement 33% 67% 0%
Aortic stenosis with low LVEF 50% 33% 17%
Aortic regurgitation with low LVEF 54% 38% 8%
Type of cardiac surgical patients who was shown in literature to benefit from 
preoperative levosimendan. Convincing evidence Some evidence Scarce/no evidence
CABG with low LVEF 92% 8% 0%
CABG plus mitral valve surgery 50% 29% 21%
Mitral valve replacement plus aortic valve replacement 17% 50% 33%
Mitral valve replacement 17% 58% 25%
Aortic stenosis with low LVEF 21% 54% 25%
Aortic regurgitation with low LVEF 17% 46% 38%
Would you suggest giving preoperative levosimendan in generally compromised 
myocardial function, including right ventricular dysfunction? 100% yes
Would you suggest giving preoperative levosimendan in high-risk surgery (recent 
myocardial infarction, age, forecasted long ischaemic period) independently of LVEF, 
EuroSCORE or cardiac score? 
67% yes
Would you suggest preoperative administration of dobutamine in high-risk cases (see 
above questions)? 92% no
Would you suggest giving levosimendan before left ventricular assist device 
implantation to support the right ventricle? 96% yes
Would you suggest to give preoperative levosimendan in pulmonary hypertension and 
right ventricle failure (e.g. during cardiac transplantation)? 92% yes
Would you suggest preoperative levosimendan in patients undergoing Mitraclip 
procedure for functional/ischaemic mitral regurgitation? 75% yes
Would you suggest preoperative levosimendan in patients undergoing transcatheter 
aortic valve implantation when LVEF is <35%? 63% no
2. Modality of administration
Where would you suggest preoperative levosimendan to be given? (multiple answers 
are allowed)
On surgical ward In ICU Any place BUT under 
hemodynamic
monitoring and clinical 
control
3/24 5/24 21/24
Which dose regimen would you recommend for preoperative levosimendan to be given 
on the day prior to surgery? (multiple answers are allowed)
Bolus + infusion Bolus alone Infusion without bolus
0/24 0/24 24/24
Which dose regimen would you recommend for preoperative levosimendan to be given 
on induction of anaesthesia? (multiple answers are allowed)
Bolus + infusion Bolus alone Infusion without bolus
7/24 0/24 19/24
In case of bolus administration, which dose would you suggest? 6 µg/kg 12 µg/kg 24 µg/kg
67% 29% 4%
What dose of levosimendan would you suggest for continuous infusion? 0.1 µg/kg/min 0.2 µg/kg/min 0.3 µg/kg/min
or higher
83% 17% 0%
How long shall the infusion last after surgery? 24 h eventually less than 24 h
(to the end of the vial)
more than 24 h
44% 50% 4%
Would you suggest a second dose in a patient
in whom a first dose had no effect? 63% no
When would you suggest a second dose to be given in a patient in whom a first dose 
worked well?
After 3−4 days
92%
Just following the first dose
8%
If acute inotropic effect is needed, what would you suggest? Increase levosimendan dose
17%
Add another inotrope
83%
If − after adequate reperfusion time − weaning from CPB cannot be easily
accomplished in a patient pretreated with levosimendan (24 h before surgery or for a 
sufficient time and with a sufficient dose), what would do next? (multiple answers are 
allowed)
IABP plus 
second inotrope
Add a 
second 
inotrope
Urge the surgeon to 
insert an IABP
(if no contraindications)
Proceed with weaning anyway and
delay decisions for some h,
awaiting the sometimes prolonged
effect of levosimendan in the further 
course
7/24 10/24 10/24 2/24
Would you suggest combining levosimendan
and phosphodiesterase inhibitors? 83% no
Alternatively: Which inotrope do you recommend as a first-line agent, if additional 
inotropic support becomes necessary in a patient treated with levosimendan? (multiple 
answers are allowed)
Dobutamine PDEI Epinephrine Dopamine Others
14/24 4/24 8/24 2/24 1/24
Would you suggest combining levosimendan and norepinephrine or vasopressin if 
vascular tone needs to be handled? 100% yes
If yes, which vasopressor approach do you suggest? The vast majority (23/24) suggests first-line norepinephrine and vasopressin only for severe 
hypotension
In a patient under beta blocker treatment requiring preoperative inotropic therapy, 
which drug would you suggest? (multiple answers are allowed)
All the respondents (24/24) favour levosimendan. Phosphodiestherase inhibitors were suggested by 
4/24, while dobutamine and dopamine were not supported at all.
Would you suggest the use of levosimendan plus IABP
in a patient with overt LCOS? 88% yes
Would you urge the surgeon to implant an IABP in a patient preoperatively treated with 
a full dose of levosimendan, if post-induction TOE still shows severely depressed 
myocardial function?
Yes No It depends (i.e. more likely in a patient with MV and/or TV
regurgitation than in a single CABG case)
50% 17% 33%
3. Management of side effects
In order to avoid arrhythmias during levosimendan infusion, what potassium target 
corridor would you suggest?
Maintaining potassium levels of > 4.0mmol/L Maintaining potassium levels of > 3.5mmol/L
92% 8%
In order to avoid hypotension during levosimendan infusion, what would you suggest 
to do? (multiple answers are allowed)
Optimising volume status 
before starting the drug 
administration
Combining a vasoactive drug Combining a beta agonist 
drug
19/24 16/24 0/24
In order to avoid hypotension during levosimendan infusion, would you suggest to stop 
ACE inhibitor therapy before operation? 63% yes
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Table 3
Ongoing clinical trials on the use of levosimendan in cardiac surgery.
Study indicators: title, acronym, NCT number
and main investigator (when available)
Patient population Patient
number
Levosimendan dose and time Comparator Endpoints
LICORN (P110138)
B. Cholley
Patients with LVEF ≤40%
undergoing CABG with or
without valve replacement
under CPB
340 0.1 μg/kg/min infusion for 24 h, started at
the time of anaesthesia induction, without
bolus application.
Placebo Composite primary endpoint including use of inotropic agents beyond 24 h
after end of study drug infusion, or need for postoperative mechanical assist
devices (IABP or others), or impossibility to wean patients from them if they
were already in use preoperatively, or the need for renal replacement therapy.
Secondary endpoints comprise mortality at days 28 and 180, each item of the
primary endpoint separately, and length of intensive care unit and hospital
stays.
Intracoronary administration of levosimendan
in cardiac surgery patients ( NCT01500785)
K. Järvelä
Patients undergoing aortic valve
and CABG surgery
50 Intracoronary 12 μg/kg infusion, initiated at
the induction of cardioplegia
Placebo Primary endpoint of change in cardiac output 15 min after separation from CPB,
compared to baseline. Secondary endpoints include change in LVEF between
baseline and 5 min after sternal closure, and cTnT/CK-MB levels of ﬁrst
postoperative morning
LEVO-CTS (NCT02025621)
R. H. Mehta
Patients undergoing CABG (LVEF
≤25%) and/or mitral valve
surgery (LVEF ≤35%)
760 0.2 μg/kg/min infusion for 1 h followed by
0.1 μg/kg/min infusion for 23 h, started
before surgery.
Placebo Two co-primary endpoints:
• All-cause death at 30 days or use of mechanical assist device to day 5
• All-cause death at 30 days, or perioperative non-fatal myocardial infarction to
day 5, or need for renal dialysis to day 30, or use of mechanical assist device to
day 5
Secondary endpoints:
• Length of intensive care unit/coronary care unit stay
• Incidence of post-operative low cardiac output syndrome
• Postoperative use of secondary inotrope
Aristotle University of Thessaloniki, Greece
K. Anastasiadis
Patients with left ventricular
dysfunction (LVEF ≤40%)
scheduled for CABG
32 0.1 μg/kg/min infusion for 24 h before
surgery
Placebo Primary endpoint of assessment of left ventricular function by transthoracic
echocardiography on 7th postoperative day. Secondary endpoints of cardiac
index, tissue perfusion, and PCWP.
HSR-LEVO (NCT00994825)
G. Landoni
High risk patients undergoing
cardiac surgery with
perioperative myocardial
dysfunction
1000 24–48 h infusion (varying doses) Placebo Primary endpoint of 30-day mortality
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335W. Toller et al. / International Journal of Cardiology 184 (2015) 323–336levosimendan in the perioperative setting had already been reviewed
and discussed by Toller et al. [65]. The recommendations of Toller
et al. [65] on the operative use of levosimendan were embraced by the
present panel of experts.
The panel thus decided to limit the present consensus to the preop-
erative use of levosimendan. The panel agreed on a series of questions
and took a vote on the following questions: (1) which patients could
beneﬁt from the preoperative use of levosimendan and in which kind
of procedures, (2) at which doses and timing should levosimendan be
administered, and ﬁnally (3) which potential side effects of a preopera-
tive use of levosimendan have to be taken into account and how to best
prevent and treat them. These were answered electronically and anon-
ymously by 24 respondents (all of the authors, with the exception of PP
andMK, to avoid any conﬂict of interest, and of RHM, because the use of
levosimendan in the U.S.A. has not yet been approved), on the basis of
(i) their experience with levosimendan, and (ii) the knowledge in the
available literature. The answers were disclosed to the group and a sec-
ond round of opinion was allowed to agree on some recommendations
(see votes by the experts in Table 2).8. Conclusions of the panel
Clinical studies show that levosimendan effectively improves gener-
al and pulmonary haemodynamics in patients undergoing cardiac sur-
gery, thereby reducing the need for inotropic agents and mechanical
circulatory support, and additionally optimising renal and hepatic func-
tion. In general, the length of stay on the ICU and in the hospital is short-
ened. Overall, levosimendan treatment is considered as a kind of “safety
net” in the surgical setting. The unique inotropic and cardioprotective
properties of levosimendan can provide sustained effects for several
days and can thus help to reduce complications in the postoperative pe-
riod. On the other hand, vasodilation occurs with this treatment, which
can necessitate the administration of vasopressors.
The panellists recommended preoperative use of levosimendan in pa-
tients with generally compromised myocardial function, including right
ventricular dysfunction. They advised against a bolus dose when used
outside the operation room. The day prior to surgery was suggested as
the optimal time point for initiation of a preoperative therapy with
levosimendan. The recommended dose of levosimendan agreed upon
was 0.1 μg/kg/min infusion for 24 h, or to the end of the vial. When
levosimendan infusion is started during or after induction of anaesthesia,
the addition of a bolus is considered to be a feasible option.
Levosimendan can be administered in any hospital setting, provided
that haemodynamic monitoring is guaranteed. In fact, as levosimendan
produces signiﬁcant dose-dependent increases in stroke volume and
cardiac output, and decreases in pulmonary capillary wedge pressure,
mean blood pressure, mean pulmonary artery pressure, mean right
atrial pressure, and total peripheral resistance [47], it should be admin-
istered in a safe and adequately monitored environment, ready to pre-
vent and treat side effects. If vasodilation occurs, the experts suggest
the combination of levosimendan with norepinephrine or vasopressin.
If additional inotropic support becomes necessary in a levosimendan-
treated patient, dobutamine should be the preferred inotrope.
In general, the data so far collected are promising, but it was noted
that only some of the clinical studies are robust, as many trials were
conducted in relatively few patients, thus the scientiﬁc evidence for
use of levosimendan is yet to be further expanded. Since all of the
meta-analyses on operative use of levosimendan to date [14,66-69]
show positive beneﬁts from levosimendan, there is a strong rationale
for further expansion of the data pool. Clinical trials currently ongoing
in Europe and the U.S.A. are expected to contribute signiﬁcantly, and
to possibly support further the existing data. In the phase of revision
of this manuscript a Bayesian network meta-analysis on the effect of
inodilatory agents on mortality was published [70] in which it was
shown that levosimendan has over 90% probability to be the best inimproving survival in cardiac surgery when compared with PDE inhibi-
tors, dobutamine, and placebo.
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